Selective blockers of SGLT2, and thus blocking 50% of renal glucose reabsorption, are in development for the treatment of diabetes (e.g. [http://www.ncbi.nlm.nih.gov/pubmed/20508640?dopt=AbstractPlus]). This evidence concerns the gene SLC5A2 and diabetes mellitus.